202 related articles for article (PubMed ID: 21483439)
1. Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist.
Parameswaran R; Yu M; Lim M; Groffen J; Heisterkamp N
Leukemia; 2011 Aug; 25(8):1314-23. PubMed ID: 21483439
[TBL] [Abstract][Full Text] [Related]
2. The molecular pharmacology of AMD11070: an orally bioavailable CXCR4 HIV entry inhibitor.
Mosi RM; Anastassova V; Cox J; Darkes MC; Idzan SR; Labrecque J; Lau G; Nelson KL; Patel K; Santucci Z; Wong RS; Skerlj RT; Bridger GJ; Huskens D; Schols D; Fricker SP
Biochem Pharmacol; 2012 Feb; 83(4):472-9. PubMed ID: 22146583
[TBL] [Abstract][Full Text] [Related]
3. Effects of inhibitors of the chemokine receptor CXCR4 on acute lymphoblastic leukemia cells in vitro.
Juarez J; Bradstock KF; Gottlieb DJ; Bendall LJ
Leukemia; 2003 Jul; 17(7):1294-300. PubMed ID: 12835717
[TBL] [Abstract][Full Text] [Related]
4. Identification of hepatic niche harboring human acute lymphoblastic leukemic cells via the SDF-1/CXCR4 axis.
Kato I; Niwa A; Heike T; Fujino H; Saito MK; Umeda K; Hiramatsu H; Ito M; Morita M; Nishinaka Y; Adachi S; Ishikawa F; Nakahata T
PLoS One; 2011; 6(11):e27042. PubMed ID: 22069486
[TBL] [Abstract][Full Text] [Related]
5. CXCR4 antagonists mobilize childhood acute lymphoblastic leukemia cells into the peripheral blood and inhibit engraftment.
Juarez J; Dela Pena A; Baraz R; Hewson J; Khoo M; Cisterne A; Fricker S; Fujii N; Bradstock KF; Bendall LJ
Leukemia; 2007 Jun; 21(6):1249-57. PubMed ID: 17410186
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of CXCR4-CXCL12 chemotaxis in melanoma by AMD11070.
O'Boyle G; Swidenbank I; Marshall H; Barker CE; Armstrong J; White SA; Fricker SP; Plummer R; Wright M; Lovat PE
Br J Cancer; 2013 Apr; 108(8):1634-40. PubMed ID: 23538388
[TBL] [Abstract][Full Text] [Related]
7. Dissecting the role of the CXCL12/CXCR4 axis in acute myeloid leukaemia.
Ladikou EE; Chevassut T; Pepper CJ; Pepper AG
Br J Haematol; 2020 Jun; 189(5):815-825. PubMed ID: 32135579
[TBL] [Abstract][Full Text] [Related]
8. Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition.
Sison EA; Magoon D; Li L; Annesley CE; Rau RE; Small D; Brown P
Oncotarget; 2014 Oct; 5(19):8947-58. PubMed ID: 25333254
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the SDF-1alpha-CXCR4 axis by the CXCR4 antagonist AMD3100 suppresses the migration of cultured cells from ATL patients and murine lymphoblastoid cells from HTLV-I Tax transgenic mice.
Kawaguchi A; Orba Y; Kimura T; Iha H; Ogata M; Tsuji T; Ainai A; Sata T; Okamoto T; Hall WW; Sawa H; Hasegawa H
Blood; 2009 Oct; 114(14):2961-8. PubMed ID: 19657116
[TBL] [Abstract][Full Text] [Related]
10. Dynamic chemotherapy-induced upregulation of CXCR4 expression: a mechanism of therapeutic resistance in pediatric AML.
Sison EA; McIntyre E; Magoon D; Brown P
Mol Cancer Res; 2013 Sep; 11(9):1004-16. PubMed ID: 23754844
[TBL] [Abstract][Full Text] [Related]
11. Can inhibition of the SDF-1/CXCR4 axis eradicate acute leukemia?
Tavor S; Petit I
Semin Cancer Biol; 2010 Jun; 20(3):178-85. PubMed ID: 20637871
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy-induced alteration of SDF-1/CXCR4 expression in bone marrow-derived mesenchymal stem cells from adolescents and young adults with acute lymphoblastic leukemia.
Ge J; Hu Y; Gui Y; Hou R; Yang M; Zeng Q; Xia R
J Pediatr Hematol Oncol; 2014 Nov; 36(8):617-23. PubMed ID: 25072364
[TBL] [Abstract][Full Text] [Related]
13. Improving chemotherapeutic efficiency in acute myeloid leukemia treatments by chemically synthesized peptide interfering with CXCR4/CXCL12 axis.
Li X; Guo H; Duan H; Yang Y; Meng J; Liu J; Wang C; Xu H
Sci Rep; 2015 Nov; 5():16228. PubMed ID: 26538086
[TBL] [Abstract][Full Text] [Related]
14. Disturbed CXCR4/CXCL12 axis in paediatric precursor B-cell acute lymphoblastic leukaemia.
van den Berk LC; van der Veer A; Willemse ME; Theeuwes MJ; Luijendijk MW; Tong WH; van der Sluis IM; Pieters R; den Boer ML
Br J Haematol; 2014 Jul; 166(2):240-9. PubMed ID: 24697337
[TBL] [Abstract][Full Text] [Related]
15. Effects of pharmacological and genetic disruption of CXCR4 chemokine receptor function in B-cell acute lymphoblastic leukaemia.
Randhawa S; Cho BS; Ghosh D; Sivina M; Koehrer S; Müschen M; Peled A; Davis RE; Konopleva M; Burger JA
Br J Haematol; 2016 Aug; 174(3):425-36. PubMed ID: 27071778
[TBL] [Abstract][Full Text] [Related]
16. A CXCR4 antagonist leads to tumor suppression by activation of immune cells in a leukemia-induced microenvironment.
Han AR; Lee JY; Kim HJ; Min WS; Park G; Kim SH
Oncol Rep; 2015 Dec; 34(6):2880-8. PubMed ID: 26398122
[TBL] [Abstract][Full Text] [Related]
17. Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML.
Agarwal A; Fleischman AG; Petersen CL; MacKenzie R; Luty S; Loriaux M; Druker BJ; Woltjer RL; Deininger MW
Blood; 2012 Sep; 120(13):2658-68. PubMed ID: 22889761
[TBL] [Abstract][Full Text] [Related]
18. Combination of imatinib with CXCR4 antagonist BKT140 overcomes the protective effect of stroma and targets CML in vitro and in vivo.
Beider K; Darash-Yahana M; Blaier O; Koren-Michowitz M; Abraham M; Wald H; Wald O; Galun E; Eizenberg O; Peled A; Nagler A
Mol Cancer Ther; 2014 May; 13(5):1155-69. PubMed ID: 24502926
[TBL] [Abstract][Full Text] [Related]
19. POL5551, a novel and potent CXCR4 antagonist, enhances sensitivity to chemotherapy in pediatric ALL.
Sison EA; Magoon D; Li L; Annesley CE; Romagnoli B; Douglas GJ; Tuffin G; Zimmermann J; Brown P
Oncotarget; 2015 Oct; 6(31):30902-18. PubMed ID: 26360610
[TBL] [Abstract][Full Text] [Related]
20. The chemokine receptor CXCR4 enhances integrin-mediated in vitro adhesion and facilitates engraftment of leukemic precursor-B cells in the bone marrow.
Shen W; Bendall LJ; Gottlieb DJ; Bradstock KF
Exp Hematol; 2001 Dec; 29(12):1439-47. PubMed ID: 11750103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
